C12N 2501/2322
Interleukin-22
Official title: Interleukin-22 (IL-22)
C12N2501/2322 (Interleukin-22) appears on 3 US grants and 10 published applications in this corpus.
Search patents in C12N- Granted patents
- 3
- Published applications
- 10
- Assignees
- 6
- Inventors
- 23
- Latest grant
- 31 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2020 | 0 | 1 |
| 2021 | 0 | 1 |
| 2022 | 0 | 1 |
| 2023 | 0 | 0 |
| 2024 | 1 | 4 |
| 2025 | 0 | 1 |
| 2026 | 2 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Culture medium and culture method for primary cells of intestinal cancer31 Mar 2026US 12,590,951 B2Precedo Pharmaceuticals Co., Ltd
- Primary gastrointestinal stromal tumor cell culture medium, culture method and application thereof6 Jan 2026US 12,517,114 B2Precedo Pharmaceuticals Co., Ltd
- Edible plant-derived nanoparticles for regulation of gut microbiota16 Jul 2024US 12,036,262 B2University of Louisville Research Foundation, Inc.
- Thymic cell compositions and methods of making3 Sep 2026US 2026/0256842 A1Thymmune Therapeutics, Inc.
- Methods of making chimeric antigen receptor-expressing cells26 Feb 2026US 2026/0055157 A1Novartis AG
- Edible plant-derived nanoparticles for regulation of gut microbiota15 May 2025US 2025/0152655 A1University of Louisville Research Foundation, Inc.
- Thymic cells and methods of making19 Dec 2024US 2024/0417687 A1Thymmune Therapeutics, Inc.
- Culture Medium and Culture Method for Human Primary Acute Myeloid Leukemia Cells17 Oct 2024US 2024/0344035 A1
Most cited
By later US patents
No patent in this class has been cited by a later US patent yet.